Marksans Pharma Ltd (MARK)

Currency in INR
162.47
+1.29(+0.80%)
Closed·
Earnings results expected in 8 days
MARK is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
160.24163.30
52 wk Range
157.76276.40
Key Statistics
Bid/Ask
162.47 / 162.90
Prev. Close
161.18
Open
161.18
Day's Range
160.24-163.3
52 wk Range
157.76-276.4
Volume
403.14K
Average Volume (3m)
843.73K
1-Year Change
-28.616%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MARK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
225.33
Upside
+38.69%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Marksans Pharma Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Marksans Pharma Ltd Company Profile

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Employees
1840
Market
India

Compare MARK to Peers and Sector

Metrics to compare
MARK
Peers
Sector
Relationship
P/E Ratio
20.8x25.5x−0.6x
PEG Ratio
14.83−0.360.00
Price/Book
2.7x2.8x2.6x
Price / LTM Sales
2.7x2.4x3.4x
Upside (Analyst Target)
36.0%14.7%42.5%
Fair Value Upside
Unlock3.9%5.0%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 225.33
(+38.69% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 7.76%
Dividend Yield
0.49%
Industry Median 0.75%
Annualized payout
0.80
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
2.20 / --
Revenue / Forecast
7.20B / --
EPS Revisions
Last 90 days

MARK Income Statement

People Also Watch

58.63
LLOS
+8.31%
377.50
RECM
+3.72%
2,593.00
MCEI
+7.24%
489.65
ANRA
-0.10%

FAQ

What Is the Marksans Pharma Ltd (MARK) Stock Price Today?

The Marksans Pharma Ltd stock price today is 162.47

What Stock Exchange Does Marksans Pharma Ltd Trade On?

Marksans Pharma Ltd is listed and trades on the India National Stock Exchange stock exchange.

What Is the Stock Symbol for Marksans Pharma Ltd?

The stock symbol for Marksans Pharma Ltd is "MARK."

Does Marksans Pharma Ltd Pay Dividends? What’s The Current Dividend Yield?

The Marksans Pharma Ltd dividend yield is 0.49%.

What Is the Marksans Pharma Ltd Market Cap?

As of today, Marksans Pharma Ltd market cap is 73.63B.

What Is Marksans Pharma Ltd's Earnings Per Share (TTM)?

The Marksans Pharma Ltd EPS (TTM) is 7.76.

When Is the Next Marksans Pharma Ltd Earnings Date?

Marksans Pharma Ltd will release its next earnings report on Feb 04, 2026.

From a Technical Analysis Perspective, Is MARK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Marksans Pharma Ltd Stock Split?

Marksans Pharma Ltd has split 1 times.

How Many Employees Does Marksans Pharma Ltd Have?

Marksans Pharma Ltd has 1840 employees.

What is the current trading status of Marksans Pharma Ltd (MARK)?

As of Jan 28, 2026, Marksans Pharma Ltd (MARK) is trading at a price of 162.47, with a previous close of 161.18. The stock has fluctuated within a day range of 160.24 to 163.30, while its 52-week range spans from 157.76 to 276.40.

What Is Marksans Pharma Ltd (MARK) Price Target According to Analysts?

The average 12-month price target for Marksans Pharma Ltd is INR225.33, with a high estimate of INR246 and a low estimate of INR210. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +38.69% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.